Announcement • Jul 13
Pliant Therapeutics, Inc. Appoints Flavia Borellini and Robert Iannone to Its Board of Directors Pliant Therapeutics, Inc. announced the appointments of Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to its Board of Directors. Dr. Borellini has more than 25 years of executive management experience in the pharmaceutical and biotechnology industries with a focus on the global development of targeted oncology drugs from preclinical to commercial stage. Dr. Borellini most recently served as Chief Executive Officer for Acerta Pharma, overseeing the successful development and approval of Calquence (acalabrutinib). Prior to this, Dr. Borellini held key senior level positions within AstraZeneca including Global Franchise Head, Hematology, where she led the global development, approval, and commercialization of Tagrisso (osimertinib). Prior to AstraZeneca, Dr. Borellini held roles of increasing responsibility at Genentech, a member of the Roche Group, where she led the development, approval and launch of Zelboraf (vemurafenib). Dr. Borellini also served as the program leader for Herceptin® (trastuzumab) and Tarceva® (erlotinib). Dr. Borellini received a Ph.D. in Pharmaceutical Chemistry and Technology from the University of Modena. In addition to Pliant, Dr. Borellini currently serves on the Board of Directors of Cantargia AP, Kartos Therapeutics and Revolution Medicines.Dr. Iannone brings more than two decades of executive leadership and clinical drug development experience to Pliant. Dr. Iannone currently serves as Executive Vice President, Research and Development and Chief Medical Officer at Jazz Pharmaceuticals, overseeing clinical operations, product development and regulatory affairs. Prior to joining Jazz, Dr. Iannone held the role of Chief Medical Officer and Head of Research and Development at Immunomedics. Prior to Immunomedics, he held roles of increasing responsibility at AstraZeneca, most recently serving as Senior Vice President and Head of Immuno-oncology, Global Medicines Development. While at AstraZeneca, Dr. Iannone oversaw the development of Imfinzi (durvalumab). Earlier in his career, Dr. Iannone held management roles at Merck, most recently Executive Director and Section Head of Oncology Clinical Development, serving as a development leader for KEYTRUDA (pembrolizumab). Dr. Iannone received his M.D. from Yale University School of Medicine with Alpha Omega Alpha honors and a Master of Science in Clinical Epidemiology from the University of Pennsylvania School of Medicine. Dr. Iannone completed his training in Pediatrics and subsequently Pediatric Hematology-Oncology at the Johns Hopkins Hospital before joining the faculty of Medicine at the University of Pennsylvania. In addition to Pliant, Dr. Iannone currently serves on the Board of Directors of Autolus Therapeutics. Board Change • Jun 17
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Independent Director Steve Krognes was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • May 12
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 3.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 3.4% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$106m net loss in 3 years). Market cap is less than US$100m (US$74.3m market cap). 
